DoseMe Selected as a Pharma 2023 Innovation Award Winner

Pharma Manufacturing Editorial Board Honors DoseMe Analytics as Top Technology

JUPITER, Fla.–(BUSINESS WIRE)–DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) today announced its DoseMe Analytics platform was named a winner of the Pharma Innovation Awards.

Pharma Manufacturing, an Endeavor Business Media brand, annually recognizes technologies contributing to advancements in risk reduction, product quality improvement, and manufacturing efficiency. The Pharma Innovation Awards are a tribute to those who listen to the needs of the market and their customers, and as a result, have distinguished themselves as leaders in pharma equipment and technology. Full list of winners in the press announcement can be found here.

From clinical trials to hospital and home care, the growing financial pressure and time constraints are affecting patient outcomes every day. In the environment therapeutic drug monitoring (TDM), manual dosing decisions can be both laborious and challenging which can make these issues worse.

“We are honored to be selected along with 12 other incredibly valuable tools that help pharma companies to develop innovative, lifesaving medicines,” stated Paul Edwards, CEO of DoseMe. “DoseMe Analytics not only empowers clinicians to optimize their therapeutic drug monitoring programs but its robust dosing platform supports clinical trial investigators in real-time, in their facilities, reducing patient dropouts and potential study failure due to dose related toxicities.”

DoseMe’s advanced Bayesian dosing platform with incorporated analytics, transforms precision dosing capabilities in clinical trials by incorporating real-time data to improve decentralized decisions and comprehensive analysis. This solution leverages a drug’s pharmacokinetics and pharmacodynamics to make a personalized adaptive dose adjustment to maximize efficacy while mitigating the risk of adverse drug events (ADE) and toxicities. This unique approach integrates seamlessly into clinical trial infrastructures to guide investigators transitioning away from traditional maximum tolerated dose trial design to model-informed selection of most appropriate patient specific dose. This approach results in a reduction of ADE’s and toxicities which improves success through all clinical trial phases ultimately benefiting patient outcomes.

For more information on dosing analytics, visit https://doseme-rx.com/why-dosemerx/product/analytics

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories

Contacts

Media contact
Alison Guzzio

484-459—3243

[email protected]